Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- death of breast cancer
研究概览
简要总结
Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy
详细描述
Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients undergoing NAC
- •Age: 18-70 yrs
- •Any menopausal status
- •Any hormal receptor status
排除标准
- •Metastasis discovered during NAC
- •Lost more than 2 blood samples during NAC and surgery
结局指标
主要结局
death of breast cancer
时间窗: Follow-up time is estimated to be up to 5 years. The duration is from the date of diagnosis to date of death of breast cancer or date of death of any cause, whichever come first.
The event is defined as death of breast cancer, which is a separate measure
次要结局
- tumor recurrence or distant metastasis(Follow-up time is estimated to be up to 5 years.The duration is from diagnosis to local recurrence or distant metastasis of breast cancer. Patients were followed up every six months in first three years, then followed up once a year.)
研究者
Liu Qiang
Professor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University